Loading
Relay Therapeutics, Inc. Stock: price and insider trades · United States
Relay Therapeutics, Inc.: what insiders have been doing
This page follows insider dealings at Relay Therapeutics, Inc. as filed with SEC (Form 4), a company from the Healthcare & Pharma sector based in United States. The group dates from 2016. From 18 October 2025 to 18 October 2026, the disclosure feed for Relay Therapeutics, Inc. logged 54 filings by 11 insiders.
There is no open-market purchase to report; the filings show 34 sales worth €106.2M by 5 insiders. The totals exclude 5 filings filed without an amount. At €99.8M, the sale published on 28 August 2026 by SVF Pauling (Cayman) Ltd is the largest of the period (2.9% of market cap).
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
Compared with its exchange (5,814 companies, median 19 filings), a count of 54 filings is above the norm. The full history, which starts in 2021, counts no purchases against 171 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 15.4 m USD and net income at -276.5 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
247
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€112M
171 ops. · all time
Who traded when
BuySaleThomas Catinazzo26 sales
Donald A. Bergstrom13 sales
Peter Rahmer10 sales
Sanjiv Patel10 sales
Adams Brian6 sales
SVF Pauling (Cayman) Ltd1 sale
Analyst consensus: bullish or bearish?
Analysts rate Relay Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$27.58.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$17.06
Analyst consensus
12 analystsStrong buy
US$20.00Target US$27.58(+62%)US$32.00
Income statement
RevenueUS$15.4M
EBITDA-US$299.2M-1948% margin
Net income-US$276.5M-1800.6% margin
Valuation
PER (forward)-10.5x
P/Book4.2x
Beta1.73
Balance sheet & cash
Market capUS$3.7B
Total debtUS$32.5M
Free Cash Flow-US$235.9M
Debt / Equity3%
Profitability & ownership
ROE-36.8%
ROA-22.9%
% insiders1.6%
% institutions110.9%
Last declaration on 8 October 2026
Declarations247 total
48,199 shares@ US$18.100.022% mcap12.8% of flowCommon StockSEC:0001193125-26-418096:0
17,511 shares@ US$18.580.0084% mcap12.3% of flowCommon StockSEC:0001193125-26-418094:0
206 shares@ US$19.260.0001% mcap0.2% of flowCommon StockSEC:0001193125-26-418094:1
96,401 shares@ US$18.740.046% mcap100.0% of flowCommonSEC144:0001950047-26-010107
93,153 shares@ US$19.390.045% mcap100.0% of flowCommonSEC144:0001950047-26-010071
17,717 shares@ US$18.940.0083% mcap14.0% of flowCommon StockSEC:0001193125-26-386464:0
8,530 shares@ US$18.970.0040% mcap7.6% of flowCommon StockSEC:0001193125-26-386473:0
48,199 shares@ US$18.940.023% mcap14.8% of flowCommon StockSEC:0001193125-26-386455:0
6,000,000 shares@ US$19.402.87% mcap48.5% of flowCommon StockSEC:0001493152-26-040513:0
4,508 shares@ US$20.030.0022% mcap12.2% of flowCommon StockSEC:0001193125-26-374645:0
50,000 shares@ US$20.570.026% mcap50.5% of flowCommonSEC144:0001950047-26-008711
6,000,000 shares@ US$20.573.05% mcap51.5% of flowCommon StockSEC144:0001493152-26-040137
48,199 shares@ US$20.330.024% mcap16.0% of flowCommon StockSEC:0001193125-26-355502:0
17,717 shares@ US$19.740.0087% mcap14.7% of flowCommon StockSEC:0001193125-26-355493:0
42,225 shares@ US$19.57290.021% mcap25.1% of flowCommonSEC144:0001950047-26-007601
30,000 shares@ US$18.78510.014% mcap17.1% of flowCommonSEC144:0001950047-26-007457
2,237 shares@ US$18.610.0011% mcap2.0% of flowCommon StockSEC:0001193125-26-326137:0
1,459 shares@ US$18.610.0007% mcap1.2% of flowCommon StockSEC:0001193125-26-326144:0
748 shares@ US$18.610.0004% mcap1.9% of flowCommon StockSEC:0001193125-26-326142:0
30,000 shares@ US$19.81380.015% mcap18.2% of flowCommonSEC144:0001950047-26-007243
66,055 shares@ US$19.5830.033% mcap39.6% of flowCommonSEC144:0001950047-26-007212
3,056 shares@ US$6.950.0005% mcap0.4% of flowCommon StockSEC:0001193125-26-298681:0
17,717 shares@ US$18.690.0083% mcap14.0% of flowCommon StockSEC:0001193125-26-298679:0
48,199 shares@ US$19.580.024% mcap15.6% of flowCommon StockSEC:0001193125-26-298681:1
8,660 shares@ US$18.710.0041% mcap7.7% of flowCommon StockSEC:0001193125-26-298688:0
25 of 247 declarations
About Relay Therapeutics, Inc.
Relay Therapeutics, Inc. (ticker: RLAY) is a United States-based biopharmaceutical company listed on the Nasdaq market. It is a clinical-stage precision-medicine company focused on discovering and developing small-molecule therapies against biologically complex targets, with a primary emphasis on oncology and selected genetic diseases. Founded in 2016, Relay was launched by scientists with deep expertise in structural biology, biophysics, and molecular simulation, with the goal of using protein motion as a basis for more effective drug discovery. The company is headquartered in Cambridge, Massachusetts, in one of the most established biotech clusters in the United States.
Relay’s core business is built around its proprietary Dynamo® platform, which combines advanced computational and experimental methods to better map protein dynamics and identify targets that have historically been difficult to drug. The company’s lead asset is zovegalisib (RLY-2608), an investigational allosteric, pan-mutant, isoform-selective PI3Kα inhibitor. That program is being developed mainly in PIK3CA-mutant HR+/HER2- breast cancer, where Relay is testing both doublet and triplet regimens. Beyond that lead oncology asset, the pipeline also includes programs in NRAS-driven solid tumors and Fabry disease, giving the company exposure to both cancer and rare-disease opportunities.
Read moreShow less
From a competitive standpoint, Relay Therapeutics is best viewed as a science-driven biotech with a differentiated discovery engine rather than a commercial-stage company. Its value proposition depends on the quality of its platform, the selectivity and clinical profile of its drug candidates, and the strength of its biomarker-driven development strategy. In a highly competitive environment that includes large pharmaceutical companies and many specialty biotech peers, success will depend on continued clinical execution, regulatory progress, and the ability to show meaningful efficacy with manageable safety and tolerability.
Recent developments have been important. In 2026, the U.S. FDA granted Breakthrough Therapy designation to zovegalisib in combination with fulvestrant for PIK3CA-mutant advanced breast cancer. Relay also reported additional clinical data supporting further development of the zovegalisib plus atirmociclib triplet in frontline metastatic breast cancer, and said its RLY-8161 program has entered clinical development in NRAS-mutant solid tumors. For investors, RLAY is a Nasdaq-listed United States biotech story with meaningful upside tied to pipeline execution, but also substantial clinical and regulatory risk, as is typical for a company still in the development stage.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
